Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
Portnoy Law Firm Announces Class Action on Behalf of Nektar Therapeutics, Inc. Investors
09:00am, Tuesday, 28'th Apr 2026
LOS ANGELES, April 28, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Nektar Therapeutics, Inc., (“Nektar” or the "Company") (NASDAQ: NKTR) investors off a class action on behalf of invest
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or a
Bragar Eagel and Squire, P. C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Nektar (NKTR) To Contact Him Directly To Discuss Their Options If you purchased or acquired
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Nektar (NKTR) To Contact Him Directly To Discuss Their Options
Critical Information: $4.14 Per-Share Loss Quantifies Alleged Investor Damages Critical Information: $4.14 Per-Share Loss Quantifies Alleged Investor Damages
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
03:33pm, Monday, 27'th Apr 2026
BENSALEM, Pa., April 27, 2026 /PRNewswire/ -- The Law Offices of Howard G.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR)
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
09:49am, Monday, 27'th Apr 2026
LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar�
NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
05:00am, Monday, 27'th Apr 2026
NEW YORK, April 27, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and D
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Sunday, 26'th Apr 2026
New York, New York--(Newsfile Corp. - April 26, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed again
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired
LOS ANGELES, April 24, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the class action filed on be
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Friday, 24'th Apr 2026
New York, New York--(Newsfile Corp. - April 24, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed again
New York, New York--(Newsfile Corp. - April 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February
